Two new academic degrees digitally defended at University of Oslo, by members of the K. G. Jebsen Colorectal Cancer Research Centre
In June, Tuva Høst Brunsell (MD) defended her PhD "Heterogeneity of prognostic biomarkers in colorectal liver metastases", Institute for Clinical Medicine, Faculty of Medicine, University of Oslo. The thesis includes three papers (Brunsell et al., Clin Colorectal Cancer 2020; Brunsell et al., Eur J Surg Oncol 2019; Berg*, Brunsell* et al., submitted). On September the 4th, Christer Anker Andreassen, defended his MSc, Institute of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo. "The functional and clinical impact of the E3 Ubiquitin ligase NEDD4 in colorectal cancer and its role in regulating PTEN and P53".
TP53 proficient colorectal cancer cells are sensitive to PARP inhibition
By examining vulnerabilities in colorectal cancer, Jørgen Smeby, Kushtrim Kryeziu, and colleagues demonstrated the efficacy of PARP inhibitors for a subgroup of colorectal cancer cell lines in a recent paper in EBioMedicine (The Lancet’s open access).
The cancer patient’s own drug sensitivity model
The cancer patient’s own drug sensitivity model: researchers from the Lothe lab and collaborators recently published a paper in Clinical Cancer Research describing ex vivo patient-derived organoids from colorectal liver metastases in a heterogeneity context. Drs. Jarle Bruun, Kushtrim Kryeziu and Peter W. Eide (photo) were shared 1st authors, and have established the PDO lineages and drug screen analyses.
Jørgen Smeby the first to defend his PhD digitally at the Institute for Cancer Research
The first digital PhD defence at the Institute for Cancer Research was held on the 20th of April 2020. Dr. Jørgen Smeby defended his thesis "Molecular subtype-dependent impact of driver mutations in colorectal cancer" submitted to the Faculty of Medicine, University of Oslo. The work was performed in the Lothe lab at the Institute for Cancer Research and the K. G. Jebsen Colorectal Cancer Research Centre.
Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer
In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.
Dr Anita Sveen received the Young Investigator prize at Onkologisk Forum for her research accomplishments
Anita Sveen received the YI prize worth 50,000 NOK at Onkologisk Forum, the annual meeting for oncologists, for her research accomplishments on computational oncology.
Michael Bretthauer er Månedens forsker i Helse Sør-Øst
Viljen til nytenkning har resultert i en strålende forskerkarriere. Tilfeldighetene gjorde at Bretthauer som nyutdannet lege fra Tyskland takket ja til turnusjobb på Porsgrunn sykehus på slutten av 90-tallet. Her spesialiserte han seg innen indremedisin og fordøyelsessykdommer. Knappe 20 år etter er han Europas eneste redaktør i et av verdens fremste medisinske tidsskrifter.
Dr. Jarle Bruun’s research profiled in the 2016 National report from the Regional Health Authorities
The report highlights clinically relevant research, and projects ongoing in the K.G. Jebsen Colorectal Cancer Research Centre were selected from the South-Eastern Norway Regional Health Authority. Specifically, Dr. Jarle Bruun's paper identifying the gene Regulator of Chromosome Condensation 2 (RCC2) as functionally important in colorectal cancer, and furthermore that changes of RCC2 at the DNA and protein level can identify clinically distinct subgroups of patients with inferior survival.
Epigenetic markers stratify colorectal cancer patients within a genetically defined poor prognostic patient group
Vedeld and co-workers show that the CpG Island Methylator Phenotype (CIMP) carry prognostic value across stages. Patients with microsatellite stable tumors with BRAF V600E mutations, defining a poor prognostic subgroup, can be further subdivided by the CIMP status. This is a study from the Lind and Lothe groups in collaboration with the clinical research team of Arild Nesbakken.
Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability
Microsatellite instability (MSI) defines a small subgroup of approximately 15% of colorectal cancers (CRC) which currently receives much attention due to its overall good response to immune-checkpoint inhibition.
Foreslår radikal omlegging av folkehelsetilbud i Norge
I en artikkel i Tidsskrift for Den norske legeforening oppfordrer Mette Kalager ved Universitetet i Oslo og Camilla Stoltenberg ved Folkehelseinstituttet til nytenkning i forbindelse med den planlagte innføringen av Norges tredje kreftscreeningprogram, screening for tykktarmskreft, som for tiden er under planlegging i regi av Helsedirektoratet.
The NordICC-study group is nominated for the category Best Scientific Work by the Felix Burda Award 2017
Centre PI Michael Bretthauer and the NordICC-study group is nominated for the prestigious German research prize The Felix Burda Award 2017 for Best Scientific Work. The prize is awarded in Berlin on the 14 of May at a gala venue broadcasted on German television.
En SMART – tarmkreftpasient, blogginnlegg fra KGJ senteret
En SMART - pasient inngår i forskningsprosjekter med mål om å forebygge tarmkreft, forutsi risiko for tilbakefall, kunne tilby bedre og mer persontilpasset behandling og utvikle bedre metoder for å oppdage tilbakefall. SMART-prosjektet er en del av K. G. Jebsen senter for tarmkreft som ledes av professor Ragnhild A. Lothe.
A retrospective pooled biomarker study to predict overall survival beyond the TNM system
K. G. Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to Oslo University Hospital in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology, Dienstmann et al., March.
Screening method not effective for older women
A paper published recently in BMJ shows no effect of sigmoidoscopy screening in women aged 60 years and older. This new finding will have implications for a future Norwegian colorectal cancer screening program, where sigmoidoscopy is one of the recommended screening methods.
Mid-term report 2016 – Cancer prevention and precision medicine
In connection with Stiftelsen Kristian Gerhard Jebsen's Mid-term evaluation of The K.G. Jebsen Colorectal Cancer Research Centre, we have issued a Mid-term report.
The Centre’s 2nd annual meeting: Towards precision medicine of colorectal cancer – Building bridges.
A successful annual meeting was held in Oslo on the 10th of November at the Grand Hotel. Ongoing projects as well as joint plans for the coming centre period were presented by guests, centre members, associated clinicians, and associated investigators.
Presentation of the Patient Advisory Board at our 2nd annual meeting in November
The K.G. Jebsen Colorectal Cancer Research Centre is proud to present our recently appointed Patient Advisory Board. The board members have own experience with the colorectal cancer disease or are next of kin.
Will there be a national screening program for colorectal cancer?
There are ongoing discussions about whether to implement a national screening program for colorectal cancer in Norway. Prof. Bretthauer has contributed in a summary of the current evidence base regarding health effects of this type of screening. A decision is expected this fall.
POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis
A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G. Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in CRC patients
Intra-patient inter-metastatic genetic heterogeneity is a pronounced feature of metastatic colorectal cancer, and the strong prognostic association reinforces its clinical relevance and places it as a key feature to be explored in future patient cohorts.
OUS award to Jarle Bruun for outstanding scientific article on colorectal cancer
Six research prizes were awarded to scientists from Oslo University Hospital in June. Jarle Bruun from Ragnhild A. Lothe's group was among the prize winners. The Norwegian research web site Forskning.no highlights this important work on colorectal cancer.
Unique study finds large differences in doctors’ screening colonoscopy performance
The first ever randomised controlled trial on colorectal cancer (CRC) screening with colonoscopy reveals significant differences between endoscopists' performances. Findings from the NordICC-study was published this week in JAMA Internal Medicine.
Encouraging new procedures in Annals of Internal Medicine
Using carbon dioxide rather than room air to distend the colon during endoscopy reduces postprocedure discomfort. Yet, today, most colonoscopies worldwide still use air insufflation. The authors speculate about why adoption of this effective, inexpensive, “low-tech” innovation has been so slow.
First EPoS study paper published
The leading scientific journal «Endoscopy» has today released the first paper from the European Polyp Surveillance (EPoS) study group. The aim of the EPoS study is to find better surveillance intervals for patients with colorectal polyps.
Tarmkreft rammer også unge – KGJ senter for tarmkreft mottar gave
Tarmkreft (= tykktarm- og endetarmskreft) er en av de kreftformer som rammer flest nordmenn hvert år, ca 3900 nye tilfeller i året. Antall tilfeller øker med alder og tarmkreft har en relativt høy gjennomsnittsalder. Men sykdommen rammer også unge.
How to perform research on IBD and colorectal cancer?
Previous studies have suggested an increased risk of colorectal cancer among persons with ulcerative colitis and Crohn's disease (collectively called Inflammatory Bowel Disease (IBD)). Several attempts have been made to estimate the magnitude of risk, but researchers within the field are facing substantial methodological challenges.
Lothe and Bretthauer substantially supported by FRIPRO
Lothe and Bretthauer are given support for the projects "Modeling tumor heterogeneity in colorectal cancer management" and "COLOSS - COLOn Screening and Surveillance: Comparative Effectiveness of Colorectal Cancer Screening and Surveillance" respectively.
Endoscopic screening for gastrointestinal cancers
Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.
Review article on alternative splicing published in Oncogene
Dr. Anita Sveen and co-workers recently published a review article about alternative splicing in cancer in the journal Oncogene. In this article, an overview of known aberrant splicing events in cancer-critical genes and their potential as cancer biomarkers is given.
Chronicle on personalised cancer medicine in Aftenposten
Norway's largest newspaper Aftenposten recently printed a chronicle on personalized cancer medicine entitled "Should every cancer patient become their own research project"?
EPoS trial has started
After one year with preparations, the European Polyp Surveillance Trial (EPoS) has started patient recruitment. The EPoS study will include 30,000 patients over the next three years. Aim of the study is to find better surveillance intervals for patients with colorectal polyps.
Supercomputing reveals the genetic code of cancer
Cancer researchers are now using one of the world's fastest computers to detect which parts of the genetic code may cause bowel and prostate cancer.
Interview with Principal Investigator Rolf Skotheim in the research magazine Apollon.
Article on colorectal cancer in BBA – Reviews on Cancer
In January 2015, "Portrait of the PI3K/AKT pathway in colorectal cancer" authored by researchers at the K.G Jebsen Colorectal Cancer Research Centre was published in the journal Biochimica et Biophysica Acta (BBA) – Reviews on Cancer.
Article in the New England Journal of Medicine
On the opening day of the Centre, Principal Investigator Michael Bretthauer and colleagues published an article entitled "Long-Term Colorectal-Cancer Mortality after Adenoma Removal" in the top journal New England Journal of Medicine (impact factor 54).
Official opening of the K.G. Jebsen Colorectal Cancer Research Centre
The K.G. Jebsen Colorectal Cancer Research Centre was officially opened on the 28th of August by the chair of the Jebsen Foundation’s board of directors, Hans Peter Jebsen. Prof. Ragnhild A. Lothe will lead the Centre together with the interdisciplinary PI team consisting of Prof. Michael Bretthauer (gastroenterologist), Prof. Arild Nesbakken (surgeon), Prof. Kjell Tveit (oncologist), and ass. Prof. Rolf I. Skotheim (bioinformatician).